about
Effect of TNF-alpha genetic variants and CCR5 Delta 32 on the vulnerability to HIV-1 infection and disease progression in Caucasian Spaniards.HIV-1/HAART-Related Lipodystrophy Syndrome (HALS) Is Associated with Decreased Circulating sTWEAK Levels.Pharmacogenetics of adverse effects due to antiretroviral drugs.Pharmacogenetics of the lipodystrophy syndrome associated with HIV infection and combination antiretroviral therapy.Evaluation of the pharmacogenetics of immune recovery in treated HIV-infected patients.Mitochondrial and apoptotic in vitro modelling of differential HIV-1 progression and antiretroviral toxicity.HIV/antiretroviral therapy-related lipodystrophy syndrome (HALS) is associated with higher RBP4 and lower omentin in plasma.Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.Involvement of the LPS-LPB-CD14-MD2-TLR4 inflammation pathway in HIV-1/HAART-associated lipodystrophy syndrome (HALS).Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapyNo relationship between TNF-α genetic variants and combination antiretroviral therapy-related lipodystrophy syndrome in HIV type 1-infected patients: a case-control study and a meta-analysis.Absence of CXCR4 C-terminal polymorphisms in HIV-1-infected and uninfected Spaniards.Proximal tubular kidney damage and tenofovir: a role for mitochondrial toxicity?Cutaneous polyarteritis nodosa in human immunodeficiency virus infection.A baseline metabolomic signature is associated with immunological CD4+ T-cell recovery after 36 months of ART in HIV-infected patients.Effect of genetic variants of CCR2 and CCL2 on the natural history of HIV-1 infection: CCL2-2518GG is overrepresented in a cohort of Spanish HIV-1-infected subjects.Polymorphism of RANTES chemokine gene promoter is not associated with long-term nonprogressive HIV-1 infection of more than 16 years.Proteomic Profile Associated with Loss of Spontaneous HIV-1 Elite ControlLipodystrophy and Insulin Resistance in Combination Antiretroviral Treated HIV-1–Infected Patients: Implication of ResistinAdipogenic/Lipid, Inflammatory, and Mitochondrial Parameters in Subcutaneous Adipose Tissue of Untreated HIV-1–Infected Long-Term NonprogressorsLeptin and adiponectin, but not IL18, are related with insulin resistance in treated HIV-1-infected patients with lipodystrophyZinc alpha-2 glycoprotein is implicated in dyslipidaemia in HIV-1-infected patients treated with antiretroviral drugsPolymorphisms in the 3′ untranslated region of the fractalkine (CX3CL1) gene and the risk of HIV-1 infection and disease progressionLack of Association of SDF-1 3???A Variant Allele With Long-Term Nonprogressive HIV-1 Infection Is Extended Beyond 16 YearsSpanish HIV-1-Infected Long-Term Nonprogressors of More Than 15 Years Have an Increased Frequency of the CX3CR1 249I Variant AllelePost-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudineHIV-1-Infected Long-Term Non-Progressors have Milder Mitochondrial Impairment and Lower Mitochondrially-Driven Apoptosis in Peripheral Blood Mononuclear Cells than Typical Progressors[Nosocomial infection by Xanthomonas maltophilia][Quadricuspid aortic valve. Presentation of a new case and review of the literature][Bordetella bronchiseptica in a patient with prostatic adenocarcinoma]Gastric toxoplasmosis in the acquired immunodeficiency syndromeImmunological and virological activity of zalcitabine and zidovudine in combination in HIV-positive people with CD4 cell counts of between 200-500 cells/mm3[Headaches with focal neurological deficits and lymphocytic pleocytosis. An underdiagnosed entity?]Circulating metabolomic profile can predict dyslipidemia in HIV patients undergoing antiretroviral therapyLipidomics Reveals Reduced Inflammatory Lipid Species and Storage Lipids after Switching from EFV/FTC/TDF to RPV/FTC/TDF: A Randomized Open-Label TrialSurveillance of transmitted drug resistance to integrase inhibitors in Spain: implications for clinical practice
P50
Q33564972-193EB878-2401-4CA6-AA5A-053AADBF69ACQ35866999-8F793E45-3ACD-4300-8C35-360AB40C169CQ37706094-84CCE51A-1170-4728-8A2C-2782D5633E14Q37945715-26373E11-F11D-4EFE-A67B-493D45560BF7Q38164430-18CA598F-7460-45EC-8516-CD2CA5F3DF35Q41276695-DCD3166F-E3B0-4E2C-94B6-6FC099B1975EQ41325832-89A5EE10-FD38-4123-A087-A0F02691AAF0Q41666586-BE65D10F-3B22-46F7-A06A-9197F5BD0C25Q42236515-C0D5A341-1271-44E4-AEE8-A3BB2E8AE49FQ42430831-9CC28823-B0D6-4F1F-B8D5-672AA111808CQ44396314-5320D04B-6850-4389-A05D-7614D6225646Q44710223-6B9ED1CC-5D99-4DA5-9C73-3F3175DC51E5Q44997975-5DF3AA84-9DC6-4933-8C8C-CDB83D8901B7Q45779806-03C9BA3B-63F1-4764-9517-A78FCD6BFBF0Q47216380-BEB0FA79-71D9-43BC-870F-67E2449DC96DQ54572402-2B18FE17-B84C-4B0A-B43A-AAE03DBFF0E8Q54627407-3485DDD8-D40F-468E-9E65-F41230D63534Q57471553-419C6948-EF0C-4C6B-B898-BE4C4652EB54Q59540568-17275605-C3AC-410E-AE98-02877299CC29Q59771024-50686DA1-7B45-46F6-9FDE-6949B68B024BQ59771032-B7518A7D-5AC0-4A7C-86DD-B4B9E2527732Q59771038-DC35F321-9D09-4BCE-BBE6-40224E1498CAQ59780356-DC3348F5-8D55-4E82-965C-05259E1375F5Q59780362-A06351F6-0838-49B0-B371-0619676F2715Q59780364-62C9A7FF-5D62-4949-8C74-D955CEE67C10Q61766680-5FD201AB-C312-482B-9FE4-B0A6DA567137Q62030632-9131D44F-48F9-4B35-B8B6-667220DAEA56Q67961175-D7B946F5-D90D-48FD-8834-998C7114EC2AQ67978161-F7E6AD59-DD72-4DD3-8056-A9D7693D486EQ71963939-F336EB74-C39F-4B08-A6B0-C67FCF777F4DQ72906693-B3CE8EDE-3979-4CC4-A1B9-8AFD04E2A963Q73805813-7BA61A1B-90E7-42FB-8BEF-5588CC0B46B5Q79832682-C59F922A-A128-4D42-81F3-3C8767A0AAF8Q88423414-2341A8EA-7C00-4E04-A5B8-BD10BC3293B5Q94450023-F8A18E7C-37D5-4540-813B-7150B4CC934AQ95409429-927A08D1-382A-425F-871F-447F4012231B
P50
description
researcher ORCID ID = 0000-0001-7808-5479
@en
wetenschapper
@nl
name
Joaquim Peraire
@ast
Joaquim Peraire
@en
Joaquim Peraire
@es
Joaquim Peraire
@nl
type
label
Joaquim Peraire
@ast
Joaquim Peraire
@en
Joaquim Peraire
@es
Joaquim Peraire
@nl
prefLabel
Joaquim Peraire
@ast
Joaquim Peraire
@en
Joaquim Peraire
@es
Joaquim Peraire
@nl
P106
P1153
57193414922
7006447463
P21
P31
P496
0000-0001-7808-5479